Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study to compare the oral bioavailability of seven prototype slow-release formulations to immediate-release tablets
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Formulation B | Experimental | Slow release (SR) tablet |
|
| Formulation C | Experimental | SR tablet |
|
| Formulation D | Experimental | SR tablet |
|
| Formulation E | Experimental | SR tablet |
|
| Formulation F | Experimental | SR tablet |
|
| Formulation G | Experimental | SR tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Formulation B: Pramipexole Slow release (SR) tablet | Drug |
| ||
| Formulation C: Pramipexole Slow release tablet |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma total exposure (AUCÏ„,ss) | up to 168 hours after each drug administration | |
| Urine total exposure (Aeτ,ss) | up to 168 hours after each drug administration | |
| Plasma maximum exposure (Cmax,ss) | up to 168 hours after each drug administration | |
| Plasma minimum exposure (Cmin,ss) | up to 168 hours after each drug administration | |
| Plasma average concentration (Cavg) | up to 168 hours after each drug administration | |
| Plasma peak to trough fluctuation (PTF) | up to 168 hours after each drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-6,11 for the immediate release (IR) formulation | day 7 of visit 2 | |
| Cmax for the IR formulation | up to 168 hours after drug administration in visit 2 | |
| Cmin for the IR formulation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Formulation H | Experimental | SR tablet |
|
| immediate release (IR) formulation | Active Comparator |
|
| Drug |
|
| Formulation D: Pramipexole Slow release tablet | Drug |
|
| Formulation E: Pramipexole Slow release tablet | Drug |
|
| Formulation F: Pramipexole Slow release tablet | Drug |
|
| Formulation G: Pramipexole Slow release tablet | Drug |
|
| Formulation H: Pramipexole Slow release tablet | Drug |
|
| Pramipexole immediate release (IR) tablets | Drug |
|
| up to 168 hours after drug administration in visit 2 |
| tmax for the IR formulation | up to 168 hours after drug administration in visit 2 |
| Urinary excretion (Ae) for the IR formulation | up to 168 hours after drug administration in visit 2 |
| tmax,4 for the SR formulation | up to 96 hours after drug administration in visit 3-5, 7 and 9 |
| t1/2,4 for the SR formulation | up to 96 hours after drug administration in visit 9 |
| Urinary excretion (Ae) for the SR formulation | up to 168 hours after drug administration |
| Number of subjects with adverse events | up to 8 days after last drug administration |
| Number of subjects with clinically significant findings in laboratory tests | up to 8 days after last drug administration |
| Number of subjects with clinically significant findings in vital signs | blood pressure, pulse rate | up to 8 days after last drug administration |
| Assessment of global tolerability by investigator on a 5-point scale | at the end of each of the visits 2 to 9 |
| ID | Term |
|---|---|
| D013607 | Tablets |
| D000077487 | Pramipexole |
| ID | Term |
|---|---|
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
| D052160 | Benzothiazoles |
| D013844 | Thiazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided